In recent times, CSF levels of Aβ42, total tau, and p-tau have been linked to clinical outcomes in investigations of healthy older people with amnestic mild cognitive impairment or mild Alzheimer's disease. The gene discussed is MAPT; the disease is Alzheimer disease.